{"schema_version":"secwatch.filing_event.v1","accession":"0001654954-23-014163","form_type":"8-K","ticker":"ZOMDF","cik":"0001684144","company_name":"Zomedica Corp.","filed_at":"2023-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.055212+00:00","generated_at":"2026-06-08T05:15:49.446984+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Zomedica Q3 revenue up 31% to record $6.3M; net loss narrows to $0.3M; NYSE listing deficiency","bullets":["Revenue of $6.3M, up 31% YoY; gross margin 69%, up from 67% sequential.","Net loss narrowed to $0.3M ($0.001/share) from $5.8M ($0.005/share) a year ago.","Non-GAAP EBITDA loss $0.3M vs $3.0M loss; adjusted non-GAAP EBITDA profit $0.3M.","Liquidity $118M; completed acquisitions of SMP (VetGuardian) and Qorvo Biotechnologies.","NYSE American notified of low share price deficiency; 30-day avg <$0.20; company plans cure."],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-23-014163","json":"https://secwatch.observer/filing/0001654954-23-014163.json","markdown":"https://secwatch.observer/filing/0001654954-23-014163.md","text":"https://secwatch.observer/filing/0001654954-23-014163.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1684144/000165495423014163/0001654954-23-014163-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1684144/000165495423014163/zom_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T05:15:49.446984+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ce551be787ba5b707d4412f4c1c5e5a0ceb3a217","claim":"Zomedica Corp. reported the quarter ended September 30, 2023 results: revenue $6.3 million.","evidence_excerpt":"EX-99.1 (PRESS RELEASE) --- EX-99.1 2 zom_ex991.htm PRESS RELEASE zom_ex991.htm EXHIBIT 99.1 Zomedica Announces Record Third Quarter 2023 Financial Results: Revenue up 31% to $6.3 Million; 69% Gross Margin, and $118 Million in Liquidity, while Making Strategic Acquisitions of Structured Monitoring Products and Qorvo Biotechnologies ANN ARBOR, MI / ACCESSWIRE /","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1684144/000165495423014163/0001654954-23-014163-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2023"},{"label":"Revenue","value":"$6.3 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}